Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.
Ahmad MoollaJasper de BoerDavid PavlovAmin AminAngela TaylorLorna GilliganBeverly HughesJohn RyanEleanor BarnesZaki Hassan-SmithJane I GroveGuruprasad P AithalAn VerrijkenSven FrancqueLuc Van GaalMatthew James ArmstrongPhillip N NewsomeJeremy F CobboldWiebke ArltMichael BiehlJeremy W TomlinsonPublished in: Alimentary pharmacology & therapeutics (2020)
Unbiased GMLVQ analysis of the urinary steroid metabolome offers excellent potential as a non-invasive biomarker approach to stage NAFLD fibrosis as well as to screen for NAFLD. A highly sensitive and specific urinary biomarker is likely to have clinical utility both in secondary care and in the broader general population within primary care and could significantly decrease the need for liver biopsy.